Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 9 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

9Total
Not Applicable (1)
P 1 (3)
P 2 (5)

Trial Status

Recruiting6
Active Not Recruiting2
Suspended1

Clinical Trials (9)

Showing 9 of 9 trials
NCT02523014Phase 2Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

NCT03604978Phase 1Active Not Recruiting

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

NCT06326190Phase 2RecruitingPrimary

177Lu-DOTATATE for Recurrent Meningioma

NCT07150806Phase 1RecruitingPrimary

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

NCT06557512Not ApplicableRecruiting

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

NCT04082520Phase 2Recruiting

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

NCT04659811Phase 2Active Not Recruiting

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

NCT07353229Phase 1Suspended

68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma

NCT02847559Phase 2Recruiting

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Showing all 9 trials

Research Network

Activity Timeline